- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
Patent holdings for IPC class A61P 25/18
Total number of patents in this class: 3486
10-year publication summary
|
149
|
199
|
241
|
215
|
260
|
278
|
253
|
242
|
193
|
78
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2718 |
95 |
| Janssen Pharmaceutica N.V. | 3231 |
63 |
| F. Hoffmann-La Roche AG | 7837 |
58 |
| H. Lundbeck A/S | 1238 |
51 |
| Intra-Cellular Therapies, Inc. | 434 |
45 |
| Taisho Pharmaceutical Co., Ltd. | 858 |
42 |
| Boehringer Ingelheim International GmbH | 4509 |
36 |
| Pfizer Inc. | 3367 |
36 |
| Glaxo Group Limited | 4364 |
32 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
32 |
| Hoffmann-La Roche Inc. | 3699 |
31 |
| Otsuka Pharmaceutical Co., Ltd. | 1502 |
30 |
| Neurocrine Biosciences, Inc. | 445 |
29 |
| AstraZeneca AB | 2832 |
27 |
| Sage Therapeutics, Inc. | 335 |
27 |
| Astellas Pharma Inc. | 1030 |
23 |
| Vanda Pharmaceuticals, Inc. | 382 |
23 |
| Merck Sharp & Dohme LLC | 3729 |
23 |
| Dainippon Sumitomo Pharma Co., Ltd. | 173 |
22 |
| Sunovion Pharmaceuticals Inc. | 247 |
22 |
| Other owners | 2739 |